Baird Reiterates an 'Outperform' on Regeneron Pharma (REGN); View ACC As Coming Out Party

Baird reiterates an 'Outperform' on Regeneron Pharma (NASDAQ: REGN) price target of $120.00.

Analyst, Christopher Raymond, said, "While much of REGN's recent outperformance (+110% YTD, NBI +15%) can be attributed to Eylea's impressive early launch, we remind investors that the next significant pipeline agent - REGN727, REGN's anti-PCSK9 antibody - will have key Phase II data this weekend at ACC. Given this, and given that Phase III trials are slated to begin 1H12, we think REGN727 is poised to become a more emergent value driver. "

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $116.46 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Beike (BEKE) PT Raised to $23 at Morgan Stanley
• Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i